102 CHAPTER 2.2 Table SI1.5 Clarity rating for START criteria. START Action Clarity rating Condition Clarity rating Explanation Clarity rating A A1 Vitamin K antagonists or direct thrombin inhibitors or factor Xa inhibitors 67% in the presence of chronic atrial fibrillation. 50% N/A A2 Aspirin (75 mg – 160 mg once daily) 92% in the presence of chronic atrial fibrillation, where Vitamin K antagonists or direct thrombin inhibitors or factor Xa inhibitors are contraindicated. 33% N/A A3 Antiplatelet therapy (aspirin or clopidogrel or prasugrel or ticagrelor) 75% with a documented history of coronary, cerebral or peripheral vascular disease. 58% N/A A4 Antihypertensive therapy 25% where systolic blood pressure consistently > 160 mmHg and/or diastolic blood pressure consistently >90 mmHg; if systolic blood pressure > 140 mmHg and /or diastolic blood pressure > 90 mmHg, if diabetic. 75% N/A A5 Statin therapy 67% with a documented history of coronary, cerebral or peripheral vascular disease, unless the patient’s status is end-of-life or age is > 85 years. 42% N/A A6 Angiotensin Converting Enzyme (ACE) inhibitor 67% with systolic heart failure and/or documented coronary artery disease. 58% N/A A7 Beta-blocker 67% with ischaemic heart disease. 75% N/A A8 Appropriate beta-blocker (bisoprolol, nebivolol, metoprolol or carvedilol) 83% with stable systolic heart failure. 67% N/A
RkJQdWJsaXNoZXIy MTk4NDMw